| Zhou, Xin |
NCT05596721: Azithromycin Treatment for Non-eosinophilic Chest Tightness Variant Asthma |
|
|
| Not yet recruiting | 4 | 248 | RoW | Azithromycin, ICS/LABA | Second Affiliated Hospital, School of Medicine, Zhejiang University | Asthma, Chest Syndrome, Azithromycin, Effect of Drug | 03/24 | 03/24 | | |
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 |
|
|
| Recruiting | 4 | 466 | RoW | Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638 | The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd. | Renal Insufficiency, Chronic | 10/25 | 03/26 | | |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
TORCHLIGHT, NCT04085276: Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment |
|
|
| Active, not recruiting | 3 | 531 | RoW | JS001, Nab-Paclitaxel, Placebo | Shanghai Junshi Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 12/24 | 12/25 | | |
NCT06323213: Efficacy and Safety Study of 610 in Patients With Severe Asthma |
|
|
| Not yet recruiting | 3 | 480 | NA | 610, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Asthma | 06/26 | 09/26 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | GB491 combined with Letrozole, Placebo combined with Letrozole | Genor Biopharma Co., Ltd. | Breast Cancer | 01/26 | 01/27 | | |
NCT05232149: A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia |
|
|
| Recruiting | 2a/2b | 30 | RoW | Orelabrutinib( lower dose), Orelabrutinib( higher dose) | Beijing InnoCare Pharma Tech Co., Ltd. | Primary Immune Thrombocytopenia | 12/23 | 12/24 | | |
NCT05528679: A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma |
|
|
| Not yet recruiting | 2 | 120 | RoW | 610 100mg, 610 300mg, placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Asthma | 09/23 | 09/23 | | |
NCT06438757: Trial of JYB1904 in Patients With Allergic Asthma |
|
|
| Recruiting | 2 | 60 | RoW | JYB1904, Omalizumab | Jemincare | Allergic Asthma | 10/25 | 10/25 | | |
NCT04835870: Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL |
|
|
| Recruiting | 2 | 78 | RoW | Zanubrutinib, BTK inhibitors, Rituximab, MabThera, Cyclophosphamide, CTX, Doxorubicin, ADM, Vincristine, VCR, Prednisone, Prednisonum | The First Affiliated Hospital of Soochow University | Non-GCB/ABC Diffuse Large B-Cell Lymphoma | 10/25 | 10/25 | | |
| Recruiting | 1/2 | 80 | RoW | TQB3454 Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 06/25 | 12/25 | | |
NCT06122831: A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) |
|
|
| Recruiting | 1/2 | 92 | RoW | TQ05105 Tablets, TQB3617 Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 12/26 | 04/27 | | |
NCT05584306: A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma |
|
|
| Active, not recruiting | 1 | 24 | RoW | 610 30mg group, 610 100mg group, 610 300mg group, Placebo 30mg group, Placebo 100mg group, Placebo 300mg group | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Asthma | 09/23 | 09/23 | | |
ELPVQFLACS, NCT06517095: Revised Capsular Polishing and Its Impact on the Positioning of the Intraocular Lens and Visual Quality Following Femtosecond Laser-assisted Cataract Surgery |
|
|
| Withdrawn | N/A | 70 | RoW | improved capsular polishing, the conventional I/A polishing | Xi'an People's Hospital (Xi'an Fourth Hospital) | Cataract | 12/25 | 12/25 | | |
NCT04417946: Peer-led Social Media Intervention to Prevent HIV Among Young Men Who Have Sex With Men (YMSM) |
|
|
| Completed | N/A | 227 | US | PrEP messages, Heath messages | Yale University, Substance Abuse and Mental Health Services Administration (SAMHSA) | Pre-Exposure Prophylaxis, Hiv, Men | 04/23 | 04/23 | | |
| Active, not recruiting | N/A | 482 | RoW | | Takeda | Multiple Myeloma, Neoplasms, Plasma Cell | 09/25 | 09/25 | | |
NCT06648317: Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions |
|
|
| Recruiting | N/A | 20 | RoW | FDG-PET | Peking University Cancer Hospital & Institute | Lung Cancer, Non-Small Cell, Lung Infection | 03/25 | 12/25 | | |
| Ding, Wei |
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 |
|
|
| Recruiting | 4 | 466 | RoW | Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638 | The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd. | Renal Insufficiency, Chronic | 10/25 | 03/26 | | |
MC1485, NCT02332980: Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas |
|
|
| Completed | 2 | 65 | US | Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Idelalisib, CAL-101, GS 1101, GS-1101, Phosphoinositide-3 Kinase Delta Inhibitor CAL-101, Zydelig, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475 | Mayo Clinic, National Cancer Institute (NCI) | Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Splenic Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia, Richter Syndrome, Waldenstrom Macroglobulinemia | 08/21 | 01/22 | | |
|
|
NCT04305444: Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas |
|
|
| Terminated | 2 | 55 | US | DTRM-555, DTRMWXHS-12, everolimus, pomalidomide | Zhejiang DTRM Biopharma | Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Richter's Transformation | 12/24 | 12/24 | | |
NCT05388006: Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation from Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2 | 30 | US | Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto | Mayo Clinic | Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma | 11/24 | 11/25 | | |
| Zhang, Lin |
KEYSTONE-002, NCT04807673: Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC |
|
|
| Recruiting | 3 | 342 | RoW | Pembrolizumab, Keytruda, Paclitaxel, Cisplatin, neoadjuvant chemoradiotherapy | Tianjin Medical University Cancer Institute and Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shanghai Chest Hospital, Ruijin Hospital, Hebei Medical University Fourth Hospital, Harbin Medical University, Liaoning Tumor Hospital & Institute, Shanxi Province Cancer Hospital, Shandong Jining No.1 People's Hospital, Weifang People's Hospital, Tianjin Medical University General Hospital, Shandong Provincial Hospital | Esophageal Squamous Cell Carcinoma | 12/23 | 05/28 | | |
PRACTICE, NCT06794684: PRogression of Atheroma Evaluated by CT Angiography and IntraCoronary Imaging tEchniques |
|
|
| Recruiting | N/A | 50000 | RoW | | Ruijin Hospital | Coronary Arterial Disease (CAD), Coronary Arteriosclerosis | 05/27 | 05/30 | | |
Pan-CHESS1801, NCT03778775: Transient Elastography (FibroTouch) for Assessing Risk of Gastroesophageal Varices Bleeding in Compensated Cirrhosis |
|
|
| Recruiting | N/A | 200 | Japan, RoW | Liver sitffness measurement, Esophagogastroduodenoscopy | Nanfang Hospital of Southern Medical University, Beijing Tsinghua Changgeng Hospital, LanZhou University, Beijing 302 Hospital, Xijing Hospital of Digestive Diseases, Wuhan Union Hospital, China, Zhujiang Hospital, Second Affiliated Hospital of Xi'an Jiaotong University, The Central Hospital of Lishui City, Xingtai People's Hospital, Seventh Medical Center of PLA Army General Hospital, Shandong Provincial Hospital, Shunde Hospital, Southern Medical University, Medistra Hospital, University of Indonesia, Ankara University, Osaka City University, Chulalongkorn University | Compensated Liver Cirrhosis, Gastroesophageal Varices Bleeding | 06/21 | 03/22 | | |
NCT04858750: Comparison and Evaluation of USSQ, OABSS, and the Drainage/Anti-reflux Effect Between Three Kinds of Ureteral D-J Stents in Patients Who Underwent URL |
|
|
| Recruiting | N/A | 150 | RoW | Placement of ureteral D-J stent after ureteroscopic holmium laser lithotripsy | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Urolithiasis, Overactive Bladder Syndrome | 04/23 | 05/23 | | |
| Recruiting | N/A | 400 | RoW | Goal-directed EN therapy, Conventional EN therapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophagus Cancer | 08/26 | 05/31 | | |
CSILS, NCT04527861: Oncologic Outcomes of Single-incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer |
|
|
| Recruiting | N/A | 710 | RoW | Single-incision Laparoscopic Surgery, SILS, Conventional Laparoscopic Surgery, CLS | Ruijin Hospital, Dongfang Hospital Affiliated to Tongji University, Fudan University, Changhai Hospital, Shengjing Hospital, RenJi Hospital, Liaoning Cancer Hospital & Institute, Zhejiang Provincial People's Hospital, Shandong Provincial Hospital, The General Hospital of Western Theater Command, Shanghai Jiao Tong University School of Medicine | Colorectal Cancer, Colon Cancer, Rectal Cancer | 04/24 | 04/29 | | |
NCT05352074: STOPS Trial: Total vs Subtotal Colectomy for Slow Transit Constipation |
|
|
| Recruiting | N/A | 202 | RoW | subtotal colectomy with cecal-rectal anastomosis, total colectomy with ileorectal anastomosis | Third Military Medical University | Slow Transit Constipation, Surgery | 12/24 | 12/26 | | |
| Wang, Feng |
NCT05049681: Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell |
|
|
| Not yet recruiting | 3 | 234 | NA | Camrelizumab, SHR-1210, Apatinib | Feng Wang | Esophageal Cancer | 12/22 | 06/23 | | |
NCT06301854: Long-term Safety of TPN171H Tablet in Erectile Dysfunction. |
|
|
| Recruiting | 3 | 472 | RoW | TPN171H, Simmerafil | Vigonvita Life Sciences | Erectile Dysfunction | 04/25 | 04/25 | | |
NCT05768503: Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC |
|
|
| Recruiting | 3 | 176 | RoW | Experimental drug, CAP, Control Rx, FOLFIRI+BEV | Sun Yat-sen University | Metastatic Microsatellite-stable Colorectal Cancer | 01/26 | 01/27 | | |
NCT05737563: PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC |
|
|
| Recruiting | 3 | 380 | RoW | PD-1 Inhibitors, Irinotecan, Capecitabine tablets | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd., Jiangsu HengRui Medicine Co., Ltd. | Esophageal Squamous Cell Carcinoma Abdominal Stage 0 | 02/26 | 02/26 | | |
NCT05918094: Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 3 | 540 | RoW | Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab | Sun Yat-sen University | Gastric Cancer | 12/26 | 12/28 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
CAP 02, NCT03736863: A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 147 | RoW | Apatinib+ SHR-1210（Camrelizumab）, Apatinib+ SHR-1316（Adebrelimab）, SHR-1316（Adebrelimab）+SHR-A2009 | The First Affiliated Hospital of Zhengzhou University | Esophageal Cancer | 06/21 | 12/25 | | |
NCT03387904: Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 120 | RoW | Anlotinib Plus Irinotecan, Irinotecan | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 12/21 | 12/22 | | |
NCT04514835: A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC |
|
|
| Not yet recruiting | 2 | 44 | RoW | Cisplatin+Capecitabine+Sintilimab | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 01/22 | 01/23 | | |
NCT04654403: Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer |
|
|
| Not yet recruiting | 2 | 337 | RoW | Camrelizumab, SHR-1210 | The First Affiliated Hospital of Zhengzhou University | Esophageal Cancer | 05/22 | 12/22 | | |
NCT04888403: Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 45 | RoW | Toripalimab+Nedaplatin+Albumin Paclitaxel | The First Affiliated Hospital of Zhengzhou University | Locally Advanced Esophageal Squamous Cell Carcinoma | 07/22 | 07/22 | | |
NCT04157140: Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC |
|
|
| Recruiting | 2 | 48 | RoW | Anlotinib, TACE+RFA | Jinglong Chen | Hepatocellular Carcinoma | 09/22 | 03/23 | | |
NCT04533490: A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 42 | NA | SHR-1210 | The First Affiliated Hospital of Zhengzhou University | Resectable Esophageal Squamous Cell Carcinoma | 10/22 | 10/23 | | |
NCT03766178: Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 45 | RoW | Nimotuzumab + SHR-1210 | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 12/22 | 09/23 | | |
NCT04984018: Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade |
|
|
| Not yet recruiting | 2 | 73 | NA | chidamide + camrelizumab | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 12/22 | 12/23 | | |
| Recruiting | 2 | 112 | RoW | Nimotuzumab, Sintilimab, Paclitaxel-albumin, Cisplatin | The First Affiliated Hospital of Zhengzhou University | Esophageal Cancer | 09/25 | 09/25 | | |
NCT05241899: A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer |
|
|
| Not yet recruiting | 2 | 56 | RoW | Fruquintinib + RC48 | The First Affiliated Hospital of Zhengzhou University | Gastric Cancer | 05/23 | 05/25 | | |
EASOAIPPGL, NCT05133349: A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory Trial |
|
|
| Recruiting | 2 | 20 | RoW | Anlotinib | Nanjing First Hospital, Nanjing Medical University | Advanced or Metastatic Paraganglioma/ Pheochromocytoma | 09/23 | 12/23 | | |
SHR-1210-02, NCT03917966: The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC |
|
|
| Recruiting | 2 | 80 | RoW | SHR-1210+docetaxel+nedaplatin, SHR-1210+Apatinib | The First Affiliated Hospital of Zhengzhou University, Jiangsu HengRui Medicine Co., Ltd. | Locally Advanced Esophageal Squamous Cell Carcinoma | 10/23 | 10/24 | | |
NCT05163483: Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer |
|
|
| Recruiting | 2 | 87 | RoW | Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab, Tucidinostat (chidamide) JS001 | Ruihua Xu | Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma | 12/23 | 12/25 | | |
NCT03810339: Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors |
|
|
| Recruiting | 2 | 35 | RoW | Toripalimab | Sun Yat-sen University | Solid Tumor, Advanced Cancer | 01/24 | 01/24 | | |
NCT05738434: Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC |
|
|
| Recruiting | 2 | 188 | RoW | Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib, Camrelizumab+Chemotherapy→Camrelizumab | The First Affiliated Hospital of Zhengzhou University | Esophageal Cancer by AJCC V8 Stage | 09/25 | 03/27 | | |
NCT06439550: Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC |
|
|
| Not yet recruiting | 2 | 42 | NA | Serplulimab, Trastuzumab, Oxaliplatin + Tegafur, SOX | The First Affiliated Hospital of Zhengzhou University | HER2-positive Gastric Cancer | 12/26 | 12/26 | | |
NCT05896787: Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) |
|
|
| Not yet recruiting | 2 | 45 | RoW | AK104, nab-paclitaxel, carboplatin, Candonilimab，Preoperative Chemotherapy | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 08/24 | 08/26 | | |
NCT06730373: First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) |
|
|
| Recruiting | 2 | 110 | RoW | Disitamab Vedotin, Sintilimab, S-1, Trastuzumab, Oxaliplatin, Capecitabine, 5-FU, Cisplatin | Qilu Hospital of Shandong University | HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma | 12/26 | 12/27 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
NCT04819971: Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC |
|
|
| Recruiting | 2 | 67 | RoW | Tirelizumab, Trastuzumab, Docetaxel, S1, Oxaliplatin | The First Affiliated Hospital of Zhengzhou University | Stomach Cancer | 12/25 | 12/25 | | |
NCT05024812: Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 1/2 | 64 | RoW | fruquintinib＋toripalimab + SOX | The First Affiliated Hospital of Zhengzhou University | Metastatic Gastric Cancer | 08/23 | 02/25 | | |
NCT05330065: A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion |
|
|
| Not yet recruiting | 1/2 | 55 | NA | bevacizumab and camrelizumab | The First Affiliated Hospital of Zhengzhou University | Malignant Pleural Effusion | 08/23 | 08/24 | | |
TQB2618-AK105-Ib-03, NCT05834543: Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 1/2 | 75 | RoW | TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin, Penpulimab injection, Paclitaxel, Cisplatin, TQB2618 injection, Penpulimab injection, TQB3617capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Esophageal Squamous Cell Carcinoma | 12/24 | 12/24 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT05441046: Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 120 | RoW | Genakumab, Tislelizumab | GeneScience Pharmaceuticals Co., Ltd. | Malignant Solid Tumors | 06/24 | 03/25 | | |
BL-M17D1-102, NCT06500052: A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | BL-M17D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Solid Tumor | 08/26 | 08/26 | | |
NCT05043675: Clinical Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients |
|
|
| Recruiting | 1 | 6 | RoW | [18F]APN-1607, [18F]PBB3 | Nanjing First Hospital, Nanjing Medical University | Alzheimer Disease | 09/24 | 09/24 | | |
NCT06050239: Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer |
|
|
| Recruiting | 1 | 10 | RoW | 177Lu-PSMA-0057 | Nanjing First Hospital, Nanjing Medical University | Metastatic Prostate Cancer | 03/25 | 03/25 | | |
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 169 | US, RoW | ABSK121-NX | Abbisko Therapeutics Co, Ltd | Solid Tumor | 03/25 | 06/25 | | |
NCT05197673: Identifying Risks of COVID-19 Outbreaks in Work Settings and the Implications for Control Measures |
|
|
| Completed | N/A | 310 | RoW | Theory of planned behaviours (TPB) based intervention | Chinese University of Hong Kong | Intention to Get SARS-CoV-2 Vaccination, Intention to Get SARS-CoV-2 Antibody Test | 04/23 | 05/23 | | |
NCT05048810: Clinical Application of 68Ga-DOTA-NT-20.3 in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma |
|
|
| Completed | N/A | 6 | RoW | 68Ga-DOTA-NT-20.3 | Nanjing First Hospital, Nanjing Medical University | Pancreatic Ductal Adenocarcinoma | 03/23 | 03/23 | | |
| Recruiting | N/A | 349 | RoW | CAPEOX adjuvant therapy, deferred CAPEOX adjuvant therapy, mFOLFOXIRI intensive adjuvant therapy | Sun Yat-sen University, Guangzhou Burning Rock Dx Co., Ltd. | Colorectal Cancer | 07/28 | 07/28 | | |
NCT06054789: Clinical Study on 68Ga-PSMA-33 for PET/CT Imaging of Prostate Cancer |
|
|
| Recruiting | N/A | 8 | RoW | 68Ga-PSMA-33, 68Ga-PSMA-617 | Nanjing First Hospital, Nanjing Medical University | Prostate Cancer | 10/23 | 10/24 | | |
NCT05593224: The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Intracranial Atherosclerotic Stenosis |
|
|
| Not yet recruiting | N/A | 156 | RoW | Intracranial Stent (Tonbridge) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Intracranial Atherosclerosis | 11/23 | 05/25 | | |
NCT05415995: A Trail of Drug-coated Balloon Treating Below The Knee Arterial Diseases |
|
|
| Recruiting | N/A | 202 | RoW | Drug eluting Balloon | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Artery Disease | 12/23 | 12/24 | | |
NCT05757505: The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis |
|
|
| Recruiting | N/A | 200 | RoW | Intracranial Stent (Tonbridge), Wingspan Stent System (Stryker Neurovascular) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Intracranial Atherosclerosis | 01/25 | 12/25 | | |
NCT05719688: Evaluate the Safety and Efficacy of Thrombectomy System in the Intravascular Treatment of Acute Ischemic Stroke |
|
|
| Recruiting | N/A | 200 | RoW | Mechanical thrombectomy | Suzhou Hengruihongyuan Medical Technology Co. LTD | Acute Ischemic Stroke | 12/23 | 12/24 | | |
NCT06438705: 99mTc Labeled FAP Targeted Molecular Probe in Early Diagnosis of Tumors |
|
|
| Recruiting | N/A | 20 | RoW | SPECT-CT imaging | Nanjing First Hospital, Nanjing Medical University | Head and Neck Tumor, Lung Cancer, Pancreatic Cancer | 01/26 | 01/26 | | |
NCT06261762: Hard and Soft Tissue Dimensional Change After Consecutive Extractions and Unassisted Socket Healing in the Esthetic Zone |
|
|
| Not yet recruiting | N/A | 20 | NA | | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Wound Heal | 06/26 | 06/26 | | |
GENIUS, NCT04849325: IBS Titan vs. PTA in Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease |
|
|
| Recruiting | N/A | 120 | RoW | Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titanâ„¢), Percutaneous Transluminal Angioplasty (PTA) Device | Biotyx Medical (Shenzhen) Co., Ltd. | Critical Limb Ischemia (CLI) | 04/24 | 10/24 | | |
| Recruiting | N/A | 30 | RoW | Recombinant Human Thyroid Stimulating Hormone | Nanjing First Hospital, Nanjing Medical University | DTC - Differentiated Thyroid Cancer, Thyroid Stimulating; Hormone, C, Radiotherapy; Complications | 03/26 | 12/26 | | |
| Recruiting | N/A | 7 | RoW | prone position | Seventh Medical Center of PLA General Hospital, Gansu Provincial Maternal and Child Health Care Hospital, Xian Children's Hospital, People's Hospital of Guangxi, Henan Provincial People's Hospital, Guangdong Provincial People's Hospital, Shenzhen Bao'an Maternal and Child Health Hospital, Zhengzhou Children's Hospital | Pediatric Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation | 05/25 | 07/25 | | |
NCT06431360: Effect of Strontium-90 Brachytherapy Combined With Hyperthermia in the Treatment of Keloid |
|
|
| Recruiting | N/A | 80 | RoW | hyperthermia, heater | Nanjing First Hospital, Nanjing Medical University | Keloid | 05/25 | 06/25 | | |
NCT06431620: Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer |
|
|
| Recruiting | N/A | 15 | RoW | Recombinant Human Thyroid Stimulating Hormone | Nanjing First Hospital, Nanjing Medical University | Recombinant Human Thyroid Stimulating Hormone | 05/26 | 12/26 | | |
| Recruiting | N/A | 200 | RoW | antibiotic-impregnated catheter | Integra LifeSciences Corporation | Hydrocephalus | 07/26 | 12/26 | | |
NCT05867589: Study of Novel PET Tracer Gallium [68Ga]/ Fluorine [18F] -FAPI-04 in the Diagnosis of Cardiovascular Diseases |
|
|
| Recruiting | N/A | 100 | RoW | 68Ga/18F-FAPI-04 | Nanjing First Hospital, Nanjing Medical University | Myocardial Fibrosis | 12/25 | 12/25 | | |
| Recruiting | N/A | 300 | RoW | an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor | The First Affiliated Hospital of Zhengzhou University | Esophageal Neoplasms | 05/24 | 05/25 | | |
| Chen, Guangyu |
NCT02968043: Efficacy of Physiotherapeutic Scoliosis Specific Exercises in Adolescent Idiopathic Scoliosis |
|
|
| Recruiting | N/A | 42 | RoW | physiotherapeutic scoliosis specific exercises, generalised physiotherapy exercises | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Xinhua Hospital Chongming Branch, Shanghai First Rehabilitation Hospital, Shanghai Yangzhi Rehabilitation Hospital, Shanghai Yangpu Daqiao Community Health Service Center | Scoliosis Idiopathic Adolescent | 12/21 | 12/21 | | |
NCT03427970: Efficacy of Three-dimensionally Integrated Exercise for Scoliosis in Patients With Adolescent Idiopathic Scoliosis |
|
|
| Recruiting | N/A | 42 | RoW | observation, three-dimensionally integrated exercise for scoliosis | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Scoliosis,Idiopathic,Adolescent | 12/21 | 12/21 | | |
NCT04539522: Efficacy of a Three-dimensionally Corrective Exercise Therapy for Scoliosis |
|
|
| Recruiting | N/A | 172 | RoW | Three-dimensionally corrective exercise for scoliosis, Conventional exercise | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Idiopathic Scoliosis | 12/21 | 09/22 | | |
NCT04251546: Prediction Model fo Screening and Diagnosis of Prostate Cancer in PSA Gray Zone Based on Serum PHI Combined With TPV |
|
|
| Recruiting | N/A | 80 | RoW | p2PSA, Ultrasonic parameters, Transperineal prostate biopsy | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Prostate Cancer, PSA | 09/22 | 09/22 | | |
| Not yet recruiting | N/A | 500 | RoW | Prostate imaging, Prostate biopsy | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | PROSTATE CANCER, Prostate Biopsy | 12/25 | 12/25 | | |
NCT06514833: Effects of Napping in Pregnant Women With Sleep Disturbances on Offspring Neurodevelopment |
|
|
| Not yet recruiting | N/A | 80 | RoW | lifestyle recommendations to nap regularly, No recommendations to nap regularly | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Sleep | 08/28 | 08/28 | | |
NCT06542783: Realistic in Generation of HEp-2 Cell Images Using Latent Diffusion Models: a Multi-center Visual Turing Test |
|
|
| Not yet recruiting | N/A | 300 | NA | referring to the results of AI model output | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Anti-nuclear Antibody, Visual Turing Tests, Artifical Intelligence | 12/25 | 06/26 | | |
NCT04534894: Single-center Clinical Study of Early Diagnosis of Diabetic Cardiomyopathy With FLIM |
|
|
| Not yet recruiting | N/A | 243 | NA | fluorescence lifetime imaging microscopy | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Diabetic Cardiomyopathies | 09/22 | 12/22 | | |
| Ma, Jie |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer |
|
|
| Terminated | 2 | 28 | RoW | Mitoxantrone Hydrochloride Liposome Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Breast Cancer | 01/23 | 01/23 | | |
